Comparison · NCT02744430-249ddf96
Arm 1 - Active vs Arm 2 - Placebo: Spontaneous Stone Passage Using Fisher's Exact Test
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 - Active vs Arm 2 - Placebo: Spontaneous Stone Passage Using Fisher's Exact Test. Trial comparisons, record NCT02744430-249ddf96. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02744430-249ddf96
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.471 | 0.262 | 0.69 | wilson | |
| Risk in group 2 | 0.313 | 0.142 | 0.556 | wilson | |
| Risk difference, group 1 minus group 2 | 0.158 | -0.163 | 0.436 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.51 | 0.622 | 3.65 | log | |
| Odds ratio, group 1 over group 2 | 1.96 | 0.471 | 8.11 | log | |
| Number needed to treat, for one more participant with the outcome on Arm 1 - Active than on Arm 2 - Placebo | 6.33 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 - Active | Mirabegron 50 mg orally once every 24 hours starting immediately~Mirabegron: Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet. | 8 | 17 | OG000 |
| Group 2 | Arm 2 - Placebo | Placebo orally once every 24 hours starting immediately~Placebo: Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet. | 5 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Spontaneous Stone Passage Using Fisher's Exact Test
- Description
- The primary outcome was stone passage rate at 30-days defined by either imaging (CT or Renal Ultrasound/KUB) or identification of stone using a straining device.
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
- NCT number
- NCT02744430
- Phases
- PHASE2
- Conditions
- Ureteral Obstruction, Flank Pain
- Interventions
- Mirabegron, Placebo
- Lead sponsor
- Baylor College of Medicine
- Results first posted
- 2022-04-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02744430?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02744430-249ddf96